Modalis Therapeutics Corporation ( (JP:4883) ) has issued an update.
Modalis Therapeutics Corporation announced a strategic financial restructuring aimed at improving its financial health by covering a significant deficit in retained earnings. The company’s board has resolved to reduce its stated capital and capital reserves by equal amounts to bolster its capital surplus, which will then be used to offset the deficit, ensuring no impact on share numbers or net asset values.
More about Modalis Therapeutics Corporation
Modalis Therapeutics Corporation is a biotechnology company listed on the Tokyo Stock Exchange. It specializes in developing innovative therapies and has a market focus on addressing genetic disorders through advanced therapeutic solutions.
YTD Price Performance: -1.96%
Average Trading Volume: 6,590,179
Technical Sentiment Consensus Rating: Buy
Current Market Cap: Yen7.42B
See more data about 4883 stock on TipRanks’ Stock Analysis page.